#### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 3/A

#### HALOZYME THERAPEUTICS INC

Form 3/A

February 11, 2005

### FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement HALOZYME THERAPEUTICS INC [HTI] Kennard Don A (Month/Day/Year) 01/18/2005 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 1588 SORRENTO VALLEY 03/19/2004 (Check all applicable) RD., SUITE 17 (Street) 6. Individual or Joint/Group 10% Owner Director \_X\_\_ Officer Other Filing(Check Applicable Line) (give title below) (specify below) \_X\_ Form filed by One Reporting Vice President, Regulatory Aff Person SAN DIEGO, CAÂ 92121 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Â 0 Common Stock D Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

| 1. Title of Derivative | 2. Date Exercisable and | 3. Title and Amount of | 4.          | 5.         | 6. Nature of Indirect |
|------------------------|-------------------------|------------------------|-------------|------------|-----------------------|
| Security               | Expiration Date         | Securities Underlying  | Conversion  | Ownership  | Beneficial            |
| (Instr. 4)             | (Month/Day/Year)        | Derivative Security    | or Exercise | Form of    | Ownership             |
|                        |                         | (Instr. 4)             | Price of    | Derivative | (Instr. 5)            |
|                        | Date Exercisable        | Title                  | Derivative  | Security:  |                       |
|                        |                         |                        | Security    | Direct (D) |                       |

### Edgar Filing: HALOZYME THERAPEUTICS INC - Form 3/A

|                     |               | Expiration<br>Date |        | Amount or<br>Number of<br>Shares |         | or Indirect (I) (Instr. 5) |   |
|---------------------|---------------|--------------------|--------|----------------------------------|---------|----------------------------|---|
| Options to Purchase | 01/02/2004(1) | 01/02/2014         | Common | 494,240                          | \$ 0.39 | D                          | Â |

### **Reporting Owners**

| Reporting Owner Name / Address   | Relationships |           |                                |       |  |
|--|---------------|-----------|--------------------------------|-------|--|
| . 0  | Director      | 10% Owner | Officer                        | Other |  |
| Kennard Don A<br>1588 SORRENTO VALLEY RD., SUITE 17<br>SAN DIEGO, CA 92121 | Â             | Â         | Vice President, Regulatory Aff | Â     |  |

Deletionship

## **Signatures**

/s/ Don A.
Kennard

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the Option vests on 1/2/2005 and the remainder vests monthly over a period of 36 months, contingent upon continued employment the Company

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2